Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, HUMALOG (insulin lispro), HUMALOG MIX 75-25 (insulin lispro), HUMALOG MIX 50-50 (insulin lispro), HUMILIN 70-30 (insulin), HUMILIN N (insulin), HUMULIN R (insulin) or GEMZAR (gemcitabine).

Abstract: Embodiments of this disclosure pertain to a strengthened glass article including a first surface and a second surface opposing the first surface defining a thickness (t) of about less than about 1.1 mm, a compressive stress layer extending from the first surface to a depth of compression (DOC) of about 0.1·t or greater, such that when the glass article fracture, it breaks into a plurality of fragments having an aspect ratio of about 5 or less. In some embodiments, the glass article exhibits an equibiaxial flexural strength of about 20 kgf or greater, after being abraded with 90-grit SiC particles at a pressure of 25 psi for 5 seconds. Devices incorporating the glass articles described herein and methods for making the same are also disclosed.

Abstract: A glass container including a body having a delamination factor less than or equal to 10 and at least one marking is described. The body has an inner surface, an outer surface, and a wall thickness extending between the outer surface and the inner surface. The marking is located within the wall thickness. In particular, the marking is a portion of the body having a refractive index that differs from a refractive index of an unmarked portion of the body. Methods of forming the marking within the body are also described.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include a glass body having a Class HGA1 hydrolytic resistance when tested according to the ISO 720:1985 testing standard. The glass body may have an interior surface and an exterior surface. The interior surface of the glass body does not comprise a boron-rich layer when the glass body is in an as-formed condition. A heat-tolerant coating may be bonded to at least a portion of the exterior surface of the glass body. The heat-tolerant coating may have a coefficient of friction of less than about 0.7 and is thermally stable at a temperature of at least 250° C. for 30 minutes.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Embodiments of this disclosure pertain to a strengthened glass article including a first surface and a second surface opposing the first surface defining a thickness (t) of about less than about 1.1 mm, a compressive stress layer extending from the first surface to a depth of compression (DOC) of about 0.1·t or greater, such that when the glass article fracture, it breaks into a plurality of fragments having an aspect ratio of about 5 or less. In some embodiments, the glass article exhibits an equibiaxial flexural strength of about 20 kgf or greater, after being abraded with 90-grit SiC particles at a pressure of 25 psi for 5 seconds. Devices incorporating the glass articles described herein and methods for making the same are also disclosed.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include a glass body having a Class HGA1 hydrolytic resistance when tested according to the ISO 720:1985 testing standard. The glass body may have an interior surface and an exterior surface. The interior surface of the glass body does not comprise a boron-rich layer when the glass body is in an as-formed condition. A heat-tolerant coating may be bonded to at least a portion of the exterior surface of the glass body. The heat-tolerant coating may have a coefficient of friction of less than about 0.7 and is thermally stable at a temperature of at least 250° C. for 30 minutes.

Abstract: Glass articles with coatings are disclosed herein. According to embodiments, a glass article may include a glass body comprising glass and having a first surface and a second surface opposite the first surface, wherein the first surface is an exterior surface of the glass body. A coating disposed on at least a portion of the exterior surface of the glass body. The coated glass article may have an effective throughput rate greater than or equal to 1.10×RT, wherein RT is the effective throughput rate of an uncoated glass article in units of parts per minute (ppm).

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may have a surface compressive stress of at least 350 MPa.

Abstract: Glass articles with coatings are disclosed herein. According to embodiments, a glass article may include a glass body comprising glass and having a first surface and a second surface opposite the first surface, wherein the first surface is an exterior surface of the glass body. A coating disposed on at least a portion of the exterior surface of the glass body. The coated glass article may have an effective throughput rate greater than or equal to 1.10×RT, wherein RT is the effective throughput rate of an uncoated glass article in units of parts per minute (ppm).

Abstract: A coated glass article and methods for producing the same are provided herein. The coated glass article includes a glass body having a first surface and a second surface opposite the first surface, wherein the first surface is an exterior surface of the glass body, and a damage-resistant coating formed by atomic layer deposition, the damage-resistant coating being disposed on at least a portion of the first surface of the glass body.

Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In embodiments, the glass composition may include 74-78 mol. % SiO2; X mol. % Al2O3, wherein X is 5-7; alkaline earth oxide comprising MgO and CaO, wherein: CaO is 0.1-1.0 mol. %; MgO is 4-7 mol. %; and a ratio (CaO (mol. %)/(CaO (mol. %)+MgO (mol. %)) is less than or equal to 0.5. The glass composition may further include Y mol. % alkali oxide, wherein the alkali oxide comprises 9-13 mol. % Na2O and less than or equal to 0.4 mol. % of a fining agent. The glass composition may be free of boron and compounds of boron.

Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In an embodiment the glass composition may include from about 67 mol. % to about 80 mol. % SiO2; from about 3 mol. % to about 13 mol. % alkaline earth oxide; from about 2 mol. % to about 10 mol. % Al2O3; from about 2 mol. % to about 18 mol. % alkali oxide, wherein the alkali oxide comprises non-zero amounts of Na2O; from 0 mol. % to about 4 mol. % B2O3; and from about 0.01 mol. % to about 1 mol. % of a fining agent.

Abstract: Laminated articles and layered articles, for example, low alkali glass laminated articles and layered articles useful for, for example, electrochromic devices are described.

Abstract: A glass-based article having an amorphous phase and a crystalline phase, and a first surface and a second surface opposing the first surface thereby defining a thickness (t) of the glass-based article. The glass-based article having a stress profile with a surface compressive stress (CS) and a maximum central tension (CT). The maximum CT is greater than or equal to 50 MPa and less than or equal to 200 MPa and is positioned within the glass-based article at a range from greater than or equal to 0.4·t and less than or equal to 0.6·t. The surface CS is greater than or equal to 200 MPa and less than or equal to 500 MPa, and a depth of compression (DOC) is from greater than or equal to 0.14·t and less than or equal to 0.25·t.

Abstract: A strengthened glass container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The strengthened glass container undergoes a strengthening process that produces compression at the surface and tension within the container wall. The strengthening process is designed such that the tension within the wall is great enough to ensure catastrophic failure of the container, thus rendering the product unusable, should sterility be compromised by a through-wall crack. The tension is greater than a threshold central tension, above which catastrophic failure of the container is guaranteed, thus eliminating any potential for violation of pharmaceutical integrity.

Abstract: A glass container comprises a glass body comprising a first region under a compressive stress extending from a surface of the glass body to a depth of compression and a second region extending from the depth of compression into a thickness of the glass body, the second region being under a tensile stress. The glass container also includes a localized compressive stress region having a localized compressive stress extending from the surface to a localized depth of compression within the body. The localized depth of compression is greater than the depth of compression of the first region. The glass container also includes a crack re-direction region extending in a predetermined propagation direction, wherein the crack re-direction region possesses a higher tensile stress than the tensile stress in the second region in a sub-region of the crack re-direction region, the sub-region extending substantially perpendicular to the predetermined propagation direction.

Abstract: A glass container comprises a glass body comprising a first region under a compressive stress extending from a surface of the glass body to a depth of compression and a second region extending from the depth of compression into a thickness of the glass body, the second region being under a tensile stress. The glass container also includes a localized compressive stress region having a localized compressive stress extending from the surface to a localized depth of compression within the body. The localized depth of compression is greater than the depth of compression of the first region. The glass container also includes a crack re-direction region extending in a predetermined propagation direction, wherein the crack re-direction region possesses a higher tensile stress than the tensile stress in the second region in a sub-region of the crack re-direction region, the sub-region extending substantially perpendicular to the predetermined propagation direction.

Abstract: A strengthened glass container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The strengthened glass container undergoes a strengthening process that produces compression at the surface and tension within the container wall. The strengthening process is designed such that the tension within the wall is great enough to ensure catastrophic failure of the container, thus rendering the product unusable, should sterility be compromised by a through-wall crack. The tension is greater than a threshold central tension, above which catastrophic failure of the container is guaranteed, thus eliminating any potential for violation of pharmaceutical integrity.

Abstract: A strengthened glass container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The strengthened glass container undergoes a strengthening process that produces compression at the surface and tension within the container wall. The strengthening process is designed such that the tension within the wall is great enough to ensure catastrophic failure of the container, thus rendering the product unusable, should sterility be compromised by a through-wall crack. The tension is greater than a threshold central tension, above which catastrophic failure of the container is guaranteed, thus eliminating any potential for violation of pharmaceutical integrity.